Clinical and molecular characterization of HER2amplified-pancreatic cancer
Authors:
- Angela ChouACAngela Chou
- Nicola WaddellNWNicola Waddell
- Mark J CowleyMCMark J Cowley
- Anthony J GillAGAnthony J Gill
- David K ChangDCDavid K Chang
- Ann-Marie PatchAPAnn-Marie Patch
- Katia NonesKatia Nones
- Jianmin WuJWJianmin Wu
- Mark PineseMPMark Pinese
- Amber L JohnsAJAmber L Johns
- David K MillerDMDavid K Miller
- Karin S KassahnKKKarin S Kassahn
Open Access
- 31 August 2013
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 5 (8) , 78
Abstract
Background: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome. Although HER2 amplification occurs in pancreatic cancer, it is inadequately characterized to exploit the potential of anti-HER2 therapies. Methods: HER2 amplification was detected and further analyzed using multiple genomic sequencing approaches. Standardized reference laboratory assays defined HER2 amplification in a large cohort of patients (n = 469) with pancreatic ductal adenocarcinoma (PDAC). Results: An amplified inversion event (1 MB) was identified at the HER2 locus in a patient with PDAC. Using standardized laboratory assays, we established diagnostic criteria for HER2 amplification in PDAC, and observed a prevalence of 2%. Clinically, HER2- amplified PDAC was characterized by a lack of liver metastases, and a preponderance of lung and brain metastases. Excluding breast and gastric cancer, the incidence of HER2-amplified cancers in the USA is >22,000 per annum. Conclusions: HER2 amplification occurs in 2% of PDAC, and has distinct features with implications for clinical practice. The molecular heterogeneity of PDAC implies that even an incidence of 2% represents an attractive target for anti-HER2 therapies, as options for PDAC are limited. Recruiting patients based on HER2 amplification, rather than organ of origin, could make trials of anti-HER2 therapies feasible in less common cancer types.Keywords
This publication has 27 references indexed in Scilit:
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature, 2012
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancerBritish Journal of Cancer, 2012
- The prognostic and predictive value of serum CA19.9 in pancreatic cancerAnnals of Oncology, 2012
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- International network of cancer genome projectsNature, 2010
- HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapyBMC Cancer, 2009
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic CancerJournal of Clinical Oncology, 2009
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJournal of Clinical Oncology, 2009
- Superhighway or Blind Alley? The Cancer Genome Atlas Releases First ResultsJNCI: Journal of the National Cancer Institute, 2008
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesScience, 2008